ClinicalTrials.gg
RecruitingNCT07822087Updated Sep 16, 2026

A Phase 1 Study of ATORM-C in Patients With Crohn's Disease

A Phase 1 interventional study of Autologous Adult Stem Cell-Derived Intestinal Organoid in Crohn's Diseases and Crohn's Disease, sponsored by ORGANOIDSCIENCES LTD.. Recruiting at 1 site in South Korea. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by ORGANOIDSCIENCES LTD. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
19 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 117 studies in Crohn Disease with a site in Korea, Republic of — 31 open to participants now, 41 under way, 26 of them phase 3. Crohn Disease · Korea, Republic of.

Planned enrollment
90th of 95
18 · median 280
Started
2026
with 2 others
Phase 1
3 of 117
2 open now
Primary completion
2028-08
later than 24 of 40 live
Registered
117th of 117
by date

Among the 117 studies in Crohn Disease with a site in Korea, Republic of, this one is the 90th largest by planned enrollment of the 95 interventional ones that give a count, is one of 3 that started in 2026, is one of 3 in phase 1, reaches primary completion later than 24 of the 40 other live ones, and was the 117th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

31 of the 117 studies in Crohn Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 19 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 117 studies in Crohn Disease with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This Phase 1 study evaluates the safety and tolerability of ATORM-C in patients with Crohn's disease. ATORM-C is an investigational product consisting of autologous adult stem cell-derived intestinal organoids. Participants will receive a single dose of ATORM-C applied directly to a target intestinal ulcer during colonoscopy. The study will also explore the effect of ATORM-C on intestinal ulcer healing.

Read the detailed description

This is an open-label, sequential dose-escalation Phase 1 study to evaluate the safety, tolerability, and exploratory efficacy of ATORM-C across three dose levels in patients with Crohn's disease. ATORM-C is manufactured by culturing and expanding autologous adult stem cell-derived intestinal organoids isolated from each participant's intestinal tissue. Participants will receive a single administration of ATORM-C directly applied to a target intestinal ulcer during colonoscopy. Primary evaluations will focus on safety and tolerability, with exploratory assessments of ATORM-C's effect on intestinal ulcer healing.

03

Conditions studied

  • Crohn's Diseases
  • Crohn's Disease

Browse trials for

Keywords

  • Crohn Disease
  • Intestinal Organoid
  • Autologous Organoid
  • Intestinal Ulcer
  • ATORM-C
  • Autologous Adult Stem Cell-Derived Intestinal Organoid
  • Dose Escalation
  • Crohn's disease
04

Who can participate

Ages eligible
19 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 19 years or older and younger than 80 years at the time of screening (male or female).
  2. Diagnosed with Crohn's disease at least 6 months prior to screening, confirmed by imaging, tissue sampling (), and/or colonoscopy.
  3. Have had an inadequate response to at least 6 months of standard treatment for Crohn's disease (such as anti-inflammatory drugs, oral , , or biologic agents). Inadequate response means failure to achieve ulcer-free endoscopy, defined as an SES-CD Ulcerated Surface Score of 0 or 1.
  4. Have active daily symptoms at screening and right before treatment, defined as either an average of 4 or more loose/liquid stools per day or an average daily abdominal pain score of 2 or more, based on the corresponding CDAI components.
  5. Meet all of the following colonoscopy findings at screening:

    • Have at least one active ulcer in an accessible area of the intestine (such as the colon or ileocecal region).
    • Have at least one ulcer with a longest diameter of 5 mm or larger.
    • Have an active ulcer segment with an endoscopic severity score (SES-CD) of 6 or higher, with an ulcer size score of 2 or higher and no narrowing or blockage (stricture score of 0) in that area.
  6. Meet all required blood test standards for cell therapy donor eligibility.
  7. Voluntarily agree to participate and sign the written form after receiving a full explanation of the study.

Exclusion criteria

Exclusion Criteria:

  1. Other Inflammatory Bowel Conditions: Diagnosed with ulcerative colitis or unclassified colitis.
  2. Surgical Needs: Require, or are expected to require, surgery for Crohn's disease or its complications.
  3. Severe Co-existing Conditions: Have a severe disease other than Crohn's disease, or an active abdominal/perianal condition (such as an undrained abscess or active fistula).
  4. Recent Surgeries: Had bowel resection within 6 months or intra-abdominal surgery within 3 months prior to screening.
  5. Procedure Inability: Unable to safely undergo bowel preparation, colonoscopy, or sedation, or have a known allergy/ to medications used during these procedures.
  6. Uncontrolled Medical Issues: Have a or poorly controlled medical condition, such as severe heart, bleeding, kidney, or liver disease, or uncontrolled diabetes.
  7. Active Severe Infection: Have an active, severe infection requiring ongoing medical treatment.
  8. Cancer History: Have a history of cancer () within 5 years before screening, except for specific low-risk cancers permitted by the protocol.
  9. Allergies to Study Treatment: Have a known severe allergy () to ATORM-C, its ingredients, or materials used in its manufacturing.
  10. Prohibited Therapies or Transplants: Are taking prohibited medications, have previously received any cell therapy product, or have received an organ transplant (except corneal transplant).
  11. Significant Blood Test Abnormalities: Have severe laboratory test abnormalities, including liver function ( or ALT ≥3 times the ), kidney function ( \<30 mL/min/1.73 m²), bleeding markers (PT >1.5), or low blood (\<50,000/mm³).
  12. Pregnancy, Breastfeeding, or : Are pregnant, breastfeeding, or unwilling to follow the protocol-specified contraception requirements during the study.
  13. Recent Clinical Trials: Received another drug or device within 4 weeks prior to screening.
  14. Investigator Judgment: Deemed unsuitable for participation by the study investigator for any other safety reason.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Low-Dose ATORM-C

    16,330 organoids (0.2 mL) per cm² of ulcer area

    Biological: Autologous Adult Stem Cell-Derived Intestinal Organoid

  • Experimental
    Medium-Dose ATORM-C

    81,650 organoids (0.2 mL) per cm² of ulcer area

    Biological: Autologous Adult Stem Cell-Derived Intestinal Organoid

  • Experimental
    High-Dose ATORM-C

    163,300 organoids (0.2 mL) per cm² of ulcer area

    Biological: Autologous Adult Stem Cell-Derived Intestinal Organoid

Interventions

  • BiologicalAutologous Adult Stem Cell-Derived Intestinal Organoid

    ATORM-C is an investigational product consisting of autologous adult stem cell-derived intestinal organoids. Participants will receive a single administration of ATORM-C applied directly to the target intestinal ulcer during colonoscopy. ATORM-C is administered with fibrin glue (Greenplast-Q) to facilitate local application to the target ulcer.

06

What researchers measure

Primary outcomes

  1. Dose-Limiting Toxicities (DLTs)

    Occurrence of dose-limiting toxicities (DLTs). A DLT is defined as any Grade 3 or higher adverse reaction according to NCI CTCAE v5.0 that is assessed as possibly, probably, or certainly related to ATORM-C. CTCAE grades range from Grade 1 (mild) to Grade 5 (death related to an adverse event), with higher grades indicating greater severity.

    Time frame: From ATORM-C administration through 4 weeks post-dose

  2. Determination of Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

    The MTD and RP2D of ATORM-C will be determined based on the occurrence of dose-limiting toxicities (DLTs) during the dose-escalation period and the overall safety and tolerability of ATORM-C.

    Time frame: From ATORM-C administration through 24 weeks post-dose

Secondary outcomes

  1. Incidence of Adverse Events (AEs) and Adverse Events of Special Interest (AESIs)

    Occurrence of treatment-emergent adverse events (TEAEs), adverse drug reactions (ADRs), serious adverse events (SAEs), serious adverse drug reactions (SADRs), adverse events of special interest (AESIs), and administration site local adverse events. Adverse events leading to discontinuation of study treatment or death will also be evaluated.

    Time frame: From ATORM-C administration through 24 weeks post-dose

  2. Changes in Clinical Laboratory Tests, Vital Signs, Physical Examinations, and 12-Lead Electrocardiograms (ECGs)

    Changes from baseline in continuous safety parameters, including clinical laboratory tests and vital signs, evaluated at protocol-specified visits. Occurrence of clinically significant abnormalities (Abnormal CS) in clinical laboratory tests, physical examinations, and 12-lead electrocardiograms (ECGs) post-dose will also be evaluated.

    Time frame: Baseline through 24 weeks post-dose, at protocol-specified visits

  3. Change from Baseline in Target Ulcer Size

    Absolute change and percentage change from baseline in the size of the target ulcer, evaluated based on the longest diameter, shortest diameter, and total surface area measured during colonoscopy at protocol-specified time points.

    Time frame: Baseline and Weeks 4, 12, and 24 post-dose

  4. Change from Baseline in Modified Global Histologic Disease Activity Score (Modified GHAS) of the Target Ulcer

    Change from baseline in the Modified Global Histologic Disease Activity Score (Modified GHAS) based on histologic evaluation of mucosal biopsy specimens collected from the target ulcer. The regional Modified GHAS ranges from 0 to 12, with higher scores indicating greater histologic disease activity.

    Time frame: Baseline and Week 24 post-dose

  5. Change from Baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) of the Target Ulcer

    Change from baseline in the Simple Endoscopic Score for Crohn's Disease (SES-CD) total score and ulcer size subscore evaluated specifically for the target ulcer via colonoscopy. The SES-CD assessed for the target ulcer evaluates 4 endoscopic variables, each scored from 0 to 3, yielding a target ulcer regional score ranging from 0 to 12. Higher scores indicate greater endoscopic disease activity.

    Time frame: Baseline and Weeks 4, 12, and 24 post-dose

  6. Proportion of Participants Achieving ≥50% Reduction from Baseline in SES-CD Score of the Target Ulcer

    Percentage of participants who achieve a 50% or greater reduction from baseline in the Simple Endoscopic Score for Crohn's Disease (SES-CD) total score for the target ulcer at Week 24 post-dose. The regional target ulcer SES-CD ranges from 0 to 12, with higher scores indicating greater endoscopic disease activity.

    Time frame: Baseline and Week 24 post-dose

  7. Proportion of Participants Achieving Endoscopic Remission of the Target Ulcer

    Percentage of participants achieving endoscopic remission of the target ulcer at Week 24 post-dose. Endoscopic remission is defined as a Simple Endoscopic Score for Crohn's Disease (SES-CD) total score of less than 2 (\<2) for the target ulcer. The regional target ulcer SES-CD ranges from 0 to 12, with higher scores indicating greater endoscopic disease activity.

    Time frame: Baseline and Weeks 4, 12, and 24 post-dose

Other outcomes

  1. Proportion of Participants Achieving a ≥100-Point Reduction from Baseline in Crohn's Disease Activity Index (CDAI)

    Percentage of participants who achieve a reduction of 100 points or greater (≥100 points) from baseline in the Crohn's Disease Activity Index (CDAI) total score at Week 24 post-dose. CDAI total scores range from 0 to over 600, with higher scores indicating greater disease activity. Frequencies and percentages will be summarized for each dose cohort and overall.

    Time frame: Baseline and Week 24 post-dose

  2. Proportion of Participants Achieving Clinical Remission Based on Crohn's Disease Activity Index (CDAI)

    Percentage of participants who achieve clinical remission, defined as a Crohn's Disease Activity Index (CDAI) total score of less than 150 (\<150) at protocol-specified time points post-dose. Higher CDAI scores indicate greater Crohn's disease activity.

    Time frame: Weeks 4, 12, and 24 post-dose

  3. Proportion of Participants Achieving Clinical Response Based on Patient-Reported Outcomes (PRO2)

    Percentage of participants who achieve a clinical response based on patient-reported outcomes (PRO2), defined as a reduction of 30% or greater (≥30%) from baseline in either the 7-day average Stool Frequency (SF) subscore or Abdominal Pain (AP) subscore, with neither subscore worsening from baseline. The SF subscore ranges from 0 to 11+ (higher scores reflect greater stool frequency), and the AP subscore ranges from 0 to 3 (higher scores indicate more severe pain).

    Time frame: Baseline, and Weeks 4, 12, and 24 post-dose

  4. Proportion of Participants Achieving Clinical Remission Based on Patient-Reported Outcomes (PRO), Defined as SF ≤2.8 and AP ≤1.0

    Percentage of participants who achieve clinical remission based on patient-reported outcomes (PRO2), defined as a 7-day average daily Stool Frequency (SF) of 2.8 or less (≤2.8) and a 7-day average Abdominal Pain (AP) score of 1.0 or less (≤1.0). Higher SF values indicate greater stool frequency, and higher AP scores indicate more severe abdominal pain.

    Time frame: Weeks 4, 12, and 24 post-dose

  5. Change and Percentage Change from Baseline in Fecal Calprotectin Levels

    Absolute change and percentage change from baseline in fecal calprotectin levels (measured in µg/g) at protocol-specified time points post-dose.

    Time frame: Baseline, and Weeks 4, 12, and 24 post-dose

  6. Change and Percentage Change from Baseline in C-Reactive Protein (CRP) Levels

    Absolute change and percentage change from baseline in C-reactive protein (CRP) levels (measured in mg/L) at protocol-specified time points post-dose.

    Time frame: Baseline, and Weeks 4, 12, and 24 post-dose

  7. Use of Rescue Medication During the Study

    Percentage of participants who use rescue medication and the amount of rescue medication used at protocol-specified visits during the study period.

    Time frame: From ATORM-C administration through 24 weeks post-dose

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Aug 2028, 23 months later.

Of 33 industry-sponsored phase 1 interventional studies under Crohn Disease, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 23 months is above that.

Counting every sponsor, half of 61 studies reached it within 22 months; a quarter within 10 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2026
First posted
Sep 16, 2026
StartEst.
Sep 2026
Primary completionEst.
Aug 2028
CompletionEst.
Aug 2028
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07822087
Lead sponsor
ORGANOIDSCIENCES LTD.
Responsible party
Sponsor
First posted
Sep 16, 2026
Start date
Sep 2026 (estimated)
Primary completion
Aug 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Sep 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion